https://www.selleckchem.com/products/kpt-185.html
To investigate the clinical outcomes of patients with hyponatremia who received supportive treatment or tolvaptan plus supportive treatment and the effects of treatment and other variables on overall survival METHODS This study included oncology patients who were hospitalized at two oncology centers between January 1, 2016 and December 31, 2019 for hyponatremia (sodium levels 135mEq/L) and who received tolvaptan plus supportive treatment (n = 22) or supportive treatment only (n = 42). The median age of all the patients was 59years